SecBot SecBot
8-K ·Filed Nov 19, 2026

LSTA

LISATA THERAPEUTICS, INC.
BEARISH
Impact 5/10
Horizonimmediate Processed2d 22h ago SEC0001140361-26-044826
8-K context-dependent: Items 3.03, 8.01
Actionable Insight ▼ Bearish

Monitor the stock's trading on a split-adjusted basis starting November 23. The reverse split is a defensive measure to maintain Nasdaq listing; watch for any subsequent capital raise or business update that could signal liquidity needs.

DirectionBearish
Confidencehigh
Horizonimmediate

Drugs in focus

LSTA drug pipeline →

MAR001/005

● Neutral Named in this 8-K
Impact
Phase
Phase 2b
Time to market
At least 3-5 years — Phase 2b data expected Q4 2027, followed by potential Phase 3 trials and regulatory filing
Next catalyst
None dated

What to watchThe November 9 stockholder vote is the immediate binary catalyst, failure to approve Series C conversion and reverse split could trigger cash settlement obligations and Nasdaq delisting risk. For MAR001/005 specifically, Phase 2b topline data is not expected until Q4 2027, over a year away. The extreme dilution (~2.39% legacy ownership) means LSTA stock is now effectively a proxy for Marea Therapeutics' pipeline, but with corporate governance overhangs that need resolving first.

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+1
Entry
$0.9100
T+0 close · Nov 19, 2026 · via day close
Latest settled
−1.22%
T+1 · $0.8989
Vs SPY
+2.42%
α at T+1
Next horizon
T+5
in 5d
  1. T+0 · Nov 19 $0.9100entry
  2. T+1 · 2d ago −1.22%α +2.42% · $0.8989
  3. T+5 · in 5d Pending
  4. T+20 · in 26d Pending
  5. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Lisata Therapeutics filed a Certificate of Amendment to effect a 1-for-15 reverse stock split, effective November 23, 2026, to regain compliance with Nasdaq listing requirements. The split reduces outstanding shares from approximately 10.8 million to 0.7 million, with no change to authorized shares or par value.

Key Facts

  • Reverse stock split ratio set at 1-for-15, approved by stockholders on November 9, 2026.
  • Effective at 12:01 a.m. ET on November 23, 2026.
  • Outstanding shares reduced from approximately 10.8 million to approximately 0.7 million.
  • No fractional shares issued; cash payment in lieu based on closing price on November 19, 2026.
  • Trading symbol LSTA unchanged; new CUSIP 128058 401.
  • Company is a clinical-stage pharmaceutical company with a market cap of $11M.

Financial Impact

Outstanding shares reduced from ~10.8M to ~0.7M; no change in total authorized shares or par value.

dilution

Risk Factors

  • Reverse split may signal financial distress or risk of delisting if share price does not stabilize above $1.00.
  • Low market cap ($11M) and clinical-stage pipeline create high execution risk.
  • Potential for increased volatility post-split due to reduced float.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
67% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001140361-26-044826
Document: ef20085899_ex3-1.htm0001140361-26-044826
Document: ef20085899_ex99-1.htm0001140361-26-044826
Document: 0001140361-26-044826-index-headers.html0001140361-26-044826
Document: 0001140361-26-044826-index.html0001140361-26-044826
Document: 0001140361-26-044826.txt0001140361-26-044826

Track record

21 reports on LSTA

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +54.62% at T+60 after the Jun 9, 2026 report. 6 of 11 went positive at some point.

Filters
  1. Nov 19, 20262d ago S-3/A Bearish 6/10 Entry $0.9507 settles Feb 19
  2. Nov 19, 20262d ago 8-K/A Neutral 3/10 Entry $0.9507 settles Feb 19
  3. Nov 19, 20262d ago 8-K Bearish 5/10 Viewing Entry $0.9100 settles Feb 18
  4. Nov 19, 20262d ago Press Release Neutral 4/10 Entry $0.9100 settles Feb 18
  5. Nov 12, 20269d ago S-3 Bearish 6/10 Entry $1.21 settles Feb 11
  6. Nov 12, 202610d ago 8-K/A Neutral 4/10 Entry $1.28 settles Feb 10
  7. Nov 9, 202612d ago DEFA14A Neutral 6/10 Entry $1.02 settles Feb 8
  8. Nov 9, 202612d ago 8-K Neutral 4/10 Entry $1.02 settles Feb 8
  9. Oct 19, 20264w ago DEF 14A Bearish 7/10 Entry $1.00 settles Jan 14
  10. Oct 14, 20265w ago 8-K Neutral 2/10 Entry $1.07 settles Jan 12
Showing 10 of 21

US Market Status

Market Closed · Opens Mon (26h 3m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 19, 2026